Mabylon AG is a Swiss biotechnology company leveraging its technology platform and unique know-how to discover and engineer novel antibody therapeutics in allergy, inflammation and neurology. The firm’s strength stems from extensive and successful experiences in both the pharmaceutical and biotech industries. Mabylon’s drug discovery goal is to rapidly create high-quality antibody libraries against validated targets from which the best functional, therapeutically relevant products are selected. To this aim, Mabylon has access to diverse sources of immune repertoires, focusing on patients with relevant conditions.

Human-derived antibodies offer unique opportunities to learn about the target’s human biology. In the case of allergy, for instance, antibodies derived from allergic patients target disease-relevant epitopes, expanding our knowledge of allergenic epitopes at a molecular level and their significance in the context of the disease. When human antibodies are not identifiable for given targets, immunization of selected animal species provides the source of our high-quality antibody libraries for functional assays.

The natural B-cell-derived antibodies are identified and rapidly cloned using B-cell screening technologies and high-throughput antibody-expression platforms. Within two to three weeks, B cell screening hits are cloned and expressed as monoclonal antibodies. The speed and versatility, as well as the subsequent downstream focus on functional assays and antibody engineering to identify the best therapeutic antibody molecules are at the heart of Mabylon’s discovery platform.